A 52-year-old woman with rheumatoid arthritis on long-term prednisolone (10 mg daily) presents with severe osteoporosis and pathological fracture of the femoral neck. Which mechanism best distinguishes glucocorticoid-induced osteoporosis from postmenopausal osteoporosis?

Explanation

## Glucocorticoid-Induced Osteoporosis vs Postmenopausal Osteoporosis ### Pathophysiological Comparison | Feature | Glucocorticoid-Induced | Postmenopausal | |---------|------------------------|----------------| | **Onset** | Rapid (within 3–6 months) | Gradual (over years) | | **Bone turnover** | **LOW** (↓ osteoblast function) | **HIGH** (↑ osteoclast activity) | | **Alkaline phosphatase** | Normal to low | Normal to elevated | | **Urinary hydroxyproline** | Normal to low | Elevated | | **Trabecular vs cortical** | **Predominantly trabecular** | Both, but trabecular more affected | | **Fracture pattern** | Early vertebral/rib fractures | Hip, spine, wrist | | **Serum calcium** | Normal (maintained) | Normal | | **PTH level** | Normal to low | Elevated (secondary hyperparathyroidism) | | **Mechanism** | ↓ Osteoblast differentiation, ↑ osteoblast apoptosis | ↓ Estrogen → ↑ osteoclast activity | ### Key Discriminating Feature **Key Point:** Glucocorticoid-induced osteoporosis is characterized by **RAPID bone loss within months** with a **LOW bone turnover state** (suppressed osteoblast function). This contrasts sharply with postmenopausal osteoporosis, which develops gradually over years with HIGH bone turnover. **High-Yield:** Glucocorticoids cause: 1. Decreased osteoblast differentiation and function 2. Increased osteoblast apoptosis 3. Impaired bone formation (low alkaline phosphatase) 4. **Preferential loss of trabecular bone** (explains early vertebral fractures) **Clinical Pearl:** A patient on chronic glucocorticoids can lose 5–10% of bone mass in the first year of therapy—far faster than postmenopausal bone loss (~1–3% per year). Vertebral compression fractures in the first 6 months of prednisolone therapy are a red flag for glucocorticoid-induced osteoporosis. **Mnemonic:** **GLUCO = SLOW TURNOVER** (suppressed osteoblasts, rapid loss). **POSTMENO = FAST TURNOVER** (activated osteoclasts, gradual loss). ### Biochemical Markers ```mermaid flowchart TD A[Chronic Glucocorticoid Use]:::action --> B[Osteoblast Suppression]:::outcome B --> C[↓ Bone Formation Markers]:::outcome C --> D[↓ Alkaline Phosphatase<br/>↓ P1NP<br/>↓ Osteocalcin]:::outcome A --> E[Rapid Trabecular Loss]:::urgent E --> F[Early Vertebral Fractures]:::urgent G[Postmenopausal State]:::action --> H[Osteoclast Activation]:::outcome H --> I[↑ Bone Resorption Markers]:::outcome I --> J[↑ CTX<br/>↑ NTX<br/>↑ Hydroxyproline]:::outcome G --> K[Gradual Mixed Loss]:::outcome ``` ### Clinical Implications - **Glucocorticoid osteoporosis**: Bone loss is **dose- and duration-dependent**; even low doses (≥7.5 mg prednisolone daily) increase fracture risk - **Prevention**: Calcium + vitamin D supplementation, bisphosphonates (alendronate) recommended for all patients on ≥7.5 mg prednisolone for >3 months - **Monitoring**: DEXA scan at baseline and 1–2 years; biochemical markers less useful in low-turnover state